5、消化系统肿瘤消化系统肿瘤 (12).pdf
《5、消化系统肿瘤消化系统肿瘤 (12).pdf》由会员分享,可在线阅读,更多相关《5、消化系统肿瘤消化系统肿瘤 (12).pdf(6页珍藏版)》请在得力文库 - 分享文档赚钱的网站上搜索。
1、 Journal of Clinical Oncology List of Issues Volume 39,Issue 15_suppl Meeting Abstract|2021 ASCO Annual Meeting IGASTROINTESTINAL CANCERGASTROESOPHAGEAL,PANCREATIC,ANDHEPATOBILIARYToripalimab with chemotherapy as first-linetreatment for advanced biliary tract tumors:Rights&PermissionsOPTIONS&TOOLSEx
2、port CitationTrack CitationAdd To FavoritesADVERTISEMENTADADVERTISEMENTLog InSubmitE-AlertsCartOpenAthens/Shibboleth MENU Article ToolsUpdate analytic results of an open-labelphase II clinical study(JS001-ZS-BC001).Wei Li,Yiyi Yu,Xiaojing Xu,Xi Guo,Yueqi Wang,Qian Li,.Show MoreAbstract Disclosurese1
3、6170Background:A phase II clinical study wasconducted to evaluate the safety and efficacy oftoripalimab,a novel PD-1 inhibitor,combined withchemotherapy in patients with advanced biliarytract cancers(aBTCs)(NCT03796429).Thepreliminary results indicated the combinationtreatment is well tolerable and
4、effective.Methods:Treatment naive patients with aBTCs receivedtoripalimab(240mg intravenously every threeweeks)combined with chemotherapy(gemcitabine 1000 mg/m2 d1,d8+S-1 40-60mgCOMPANION ARTICLESNo companion articlesARTICLE CITATIONDOI:10.1200/JCO.2021.39.15_suppl.e16170Journal of Clinical Oncology
5、 39,no.15_supplPublished online May 28,2021.WE RECOMMENDADVERTISEMENTEmployer:Merritt HawkinsApply for this job Employer:Potomac Oncology&HematologyApply for this job Hematology-Oncology OpportunityJust Outside of ChicagoRockford,Illinois N/AA reputable integrated health system seekinga board-certif
6、ied or board-eligiblehematologist-oncologist to join its team.Oncology&Hematology AssociatePositionRockville,Maryland Competitive SalaryThis position offers a competitive base salary,a comprehensive benefits package,exceptional productivity incentives,and apartnership track.Hematology/Oncology-at th
7、e Beach inLow Tax Delaware!Delaware(US);Family-oriented resort area inbeautiful south coastal DelawareAbstractBRAF/MEK Targeting May YieldBenefit in Treating Biliary TractCancerBy Caroline Helwick,The ASCO Post,2019Efficacy,Safety,and CorrelativeBiomarkers of Toripalimab inPreviously Treated Recurre
8、nt orMetastatic NasopharyngealCarcinoma:A Phase II Clinical Trial(POLARIS-02)Feng-Hua Wang et al.,J Clin Oncol,2021BRAF/MEK Targeting May YieldBenefit in Treating Biliary TractCancerBy Caroline Helwick et al.,Hepatobiliary Cancer,2019bid D1-14,Q21d).The treatment continued untilthe disease progress
9、or having intolerable effects.The primary endpoints of the study wereprogression free survival(PFS)and overall survival(OS).The secondary endpoints were objectiveresponse rate(ORR),safety and treatmentbiomarkers.Results:At data cutoff(January 24,2021),fifty aBTC patients were enrolled atShanghai Zho
10、ngshan Hospital.Among thesepatients,56%are males.The median age of thestudy participants was 62 years of age.Themedian follow-up time was 10 months(rangedfrom 4 to 19 months).The primary tumor type wasintrahepatic cholangiocarcinoma(ICC)accountingfor 48%of total cases,followed by gallbladdercancer(G
11、BC)(40.0%),and extrahepaticcholangiocarcinoma(ECC)(12.0%).At the time ofdata collection,48 eligible patients were includedfor data analysis.The median PFS was 7.0 months(95%CI,5.5-9.1 months)and median OS was16.0 months(95%CI,12.1 to unreachable).TheORR was 27.1%and disease control rate was87.5%incl
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 5、消化系统肿瘤消化系统肿瘤 12 消化系统 肿瘤 12
限制150内